Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mereo Biopharma Group Plc ADR (NQ: MREO ) 3.780 -0.030 (-0.79%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 857,988 Open 3.820 Bid (Size) 3.710 (5) Ask (Size) 3.900 (6) Prev. Close 3.810 Today's Range 3.765 - 3.890 52wk Range 1.070 - 4.500 Shares Outstanding 584,908,239 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market June 14, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session June 12, 2024 Via Benzinga Performance YTD +64.35% +64.35% 1 Month -2.83% -2.83% 3 Month +27.27% +27.27% 6 Month -2.83% -2.83% 1 Year +204.84% +204.84% More News Read More MicroMarvel: Mereo BioPharma - Analysts Favorite January 16, 2024 Via Talk Markets Uber To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Wednesday June 12, 2024 Via Benzinga Why Oracle Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket June 12, 2024 Via Benzinga Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) June 11, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference May 30, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update May 15, 2024 From Mereo BioPharma Group plc Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's After-Market Session April 30, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session April 29, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session April 24, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session April 22, 2024 Via Benzinga Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 03, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update March 27, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference March 05, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 26, 2024 Via Benzinga Booz Allen Hamilton Posts Upbeat Results, Joins AppFolio, Gentex And Other Big Stocks Moving Higher On Friday January 26, 2024 Via Benzinga Topics Stocks Exposures US Equities Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments January 08, 2024 From Mereo BioPharma Group plc Via GlobeNewswire Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update October 23, 2023 From Mereo BioPharma Group plc Via GlobeNewswire Why Is Mereo BioPharma Stock Trading Higher Today? October 16, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session October 16, 2023 Via Benzinga Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session October 16, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday October 16, 2023 Via InvestorPlace Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) October 14, 2023 From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma Via GlobeNewswire Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) October 09, 2023 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
